Market atlas / Senolytics / Navitoclax

Navitoclax (senolytic, ABT-263)

de-novosmall-moleculesenolyticbcl2-bclxl-inhibition● senescent-cell-burden

Stage by geography

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKJPCHILKR

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	RCT	2017-10-31	not published
UK	RCT	2017-10-31	not published
JP	RCT	not dated	not published
CH	RCT	not dated	not published
IL	RCT	not dated	not published
KR	RCT	not dated	not published

Biomarker trends

no biomarker readings yet

Studies

The studies on Navitoclax, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Arms A and B: Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at Week 24 (SVR35W24)	CH, IL, JP, KR, UK
Percentage of Participants With Adverse Events	IL, JP, KR, US
Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24)	IL, JP, KR, UK
Progression-free survival	IL, UK
Number of Participants with Dose Limiting Toxicities (DLT) (Part 1 and Part 2)	JP, UK
Maximum Observed Plasma Concentration (Cmax) of Navitoclax (Part 2 and 5)	JP, UK
Maximum Observed Plasma Concentration (Cmax) of Celecoxib (Part 4)	JP, UK
Time to Cmax (peak time, Tmax) of Navitoclax (Part 2 and 5)	JP, UK
Time to Cmax (peak time, Tmax) of Celecoxib (Part 4)	JP, UK
Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24	IL, KR

Connections

Trajectory

2017

Relatedshares a mechanism with Dasatinib

NCT03222609 · machine-extracted

2017

ProfileNavitoclax (senolytic, ABT-263)

NCT03222609 · machine-extracted

2017

MarketUK: rct (clinical trials (highest phase 2))

NCT03222609 · machine-extracted

2017

MarketUS: rct (clinical trials (highest phase 2))

NCT03222609 · machine-extracted

2026

MarketCH: rct (clinical trials (highest phase 3))

NCT04468984 · machine-extracted

2026

MarketIL: rct (clinical trials (highest phase 2))

NCT03222609 · machine-extracted

2026

MarketJP: rct (clinical trials (highest phase 2))

NCT03222609 · machine-extracted

2026

MarketKR: rct (clinical trials (highest phase 2))

NCT03222609 · machine-extracted

Get into the weeds: raw observations + provenance

navi_edge_dasa  2026-06-29  kind=edge  verify=M
   both senolytics
   source NCT03222609  https://clinicaltrials.gov/study/NCT03222609

navi_facets  2026-06-29  kind=facets  verify=M
   Navitoclax facets
   source NCT03222609  https://clinicaltrials.gov/study/NCT03222609

navi_uk  2026-06-29  kind=geography_stage  verify=M
   Navitoclax: UK phase 2 trials [NCT03222609]
   source NCT03222609  https://clinicaltrials.gov/study/NCT03222609

navi_us  2026-06-29  kind=geography_stage  verify=M
   Navitoclax: US phase 2 trials [NCT03222609]
   source NCT03222609  https://clinicaltrials.gov/study/NCT03222609

ctsearch__CH__dev_navitoclax  2026-07-10  kind=geography_stage  verify=M
   navitoclax: 1 registered trial(s) in CH, highest phase 3 [NCT04468984]
   source NCT04468984  https://clinicaltrials.gov/study/NCT04468984

ctsearch__IL__dev_navitoclax  2026-07-10  kind=geography_stage  verify=M
   navitoclax: 6 registered trial(s) in IL, highest phase 2 [NCT03222609]
   source NCT03222609  https://clinicaltrials.gov/study/NCT03222609

ctsearch__JP__dev_navitoclax  2026-07-10  kind=geography_stage  verify=M
   navitoclax: 5 registered trial(s) in JP, highest phase 2 [NCT03222609]
   source NCT03222609  https://clinicaltrials.gov/study/NCT03222609

ctsearch__KR__dev_navitoclax  2026-07-10  kind=geography_stage  verify=M
   navitoclax: 5 registered trial(s) in KR, highest phase 2 [NCT03222609]
   source NCT03222609  https://clinicaltrials.gov/study/NCT03222609